- 专利标题: Pharmaceutical combination of everolimus with dactolisib
-
申请号: US15575703申请日: 2016-05-20
-
公开(公告)号: US10576076B2公开(公告)日: 2020-03-03
- 发明人: David Glass , Joan Mannick , Leon Murphy
- 申请人: David Glass , Joan Mannick , Leon Murphy
- 申请人地址: CH Basel
- 专利权人: Novartis AG
- 当前专利权人: Novartis AG
- 当前专利权人地址: CH Basel
- 代理机构: Dechert LLP
- 代理商 Andrea L. C. Reid
- 国际申请: PCT/IB2016/052980 WO 20160520
- 国际公布: WO2016/185443 WO 20161124
- 主分类号: A61K31/4745
- IPC分类号: A61K31/4745 ; A61K31/436
摘要:
The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto.
公开/授权文献
- US20180289694A1 PHARMACEUTICAL COMBINATION OF EVEROLIMUS WITH DACTOLISIB 公开/授权日:2018-10-11
信息查询
IPC分类: